Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1993-7-1
|
pubmed:abstractText |
Hyperinsulinaemia and insulin resistance are associated with essential hypertension irrespective of obesity and non-insulin-dependent diabetes mellitus. One of the mechanisms whereby hyperinsulinaemia may play a role in the increase in blood pressure, is an increased activity of the sympathetic nervous system. The authors studied the incidence of hyperinsulinaemia, and the possibility of modulating it by 12-week administration of the ACE inhibitor (ACEI) lisinopril (Prinivil by MSD) at a dose of 20-40 mg/day. Compared with normotensive subjects, hypertensives showed a degree of hyperinsulinaemia and insulin resistance (higher blood glucose at higher immunoreactive insulin and C-peptide concentrations, and a higher IRI/blood glucose ratio) as well as manifestations of enhanced sympathetic activity (higher adrenaline levels). Lisinopril had a favourable effect not only on blood pressure but, also, on hyperinsulinaemia and adrenaline levels. It can be reasonably concluded that therapy with ACEI, in addition to its antihypertensive effect, may also favourably modulate some pathogenic and metabolic factors in essential hypertension.
|
pubmed:language |
cze
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/C-Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Catecholamines,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Lisinopril
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0010-8650
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
75-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8388786-Adult,
pubmed-meshheading:8388786-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:8388786-Blood Glucose,
pubmed-meshheading:8388786-Blood Pressure,
pubmed-meshheading:8388786-C-Peptide,
pubmed-meshheading:8388786-Catecholamines,
pubmed-meshheading:8388786-Dipeptides,
pubmed-meshheading:8388786-Female,
pubmed-meshheading:8388786-Humans,
pubmed-meshheading:8388786-Hypertension,
pubmed-meshheading:8388786-Insulin,
pubmed-meshheading:8388786-Lisinopril,
pubmed-meshheading:8388786-Male,
pubmed-meshheading:8388786-Middle Aged
|
pubmed:year |
1993
|
pubmed:articleTitle |
[Control of hyperinsulinemia in essential hypertension using the angiotensin-converting enzyme inhibitor, lisinopril].
|
pubmed:affiliation |
II. interní klinika a kardiologická laborator 1. lékarské fakulty Univerzity Karlovy, Praha, Ceská republika.
|
pubmed:publicationType |
Journal Article,
English Abstract
|